{"transactions":[{"id":4627966,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-29T01:36:32.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a \"change in control\" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025."}],"balance_after":25000,"derivative":{"exercise_price":8.58,"exercise_date":"2026-09-24","expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-26-001296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655366/000173112226001296/ownership.xml","form_type":"4"}},{"id":4627965,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-29T01:36:32.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a \"change in control\" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025."}],"balance_after":25000,"derivative":{"exercise_price":5.36,"exercise_date":"2026-09-24","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-26-001296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655366/000173112226001296/ownership.xml","form_type":"4"}},{"id":4627964,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-29T01:36:32.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a \"change in control\" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025."}],"balance_after":25000,"derivative":{"exercise_price":8.57,"exercise_date":"2026-09-24","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-26-001296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655366/000173112226001296/ownership.xml","form_type":"4"}},{"id":4627963,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-29T01:36:32.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a \"change in control\" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025."}],"balance_after":20000,"derivative":{"exercise_price":10.09,"exercise_date":"2026-09-24","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001731122-26-001296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655366/000173112226001296/ownership.xml","form_type":"4"}},{"id":941911,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T22:26:26.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a second regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares."}],"balance_after":12500,"derivative":{"exercise_price":8.58,"exercise_date":"2026-01-06","expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001731122-26-000035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000035/ownership.xml","form_type":"4"}},{"id":941923,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T17:27:25.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2025, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a Second Regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares."}],"balance_after":125000,"derivative":{"exercise_price":8.58,"exercise_date":"2026-01-06","expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001731122-26-000036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112226000036/ownership.xml","form_type":"4"}},{"id":1024264,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-04T00:42:50.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 20, 2024, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Readout of AV3-71-SZ-001 schizophrenia study. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares."}],"balance_after":25000,"derivative":{"exercise_price":5.36,"exercise_date":"2025-10-02","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001731122-25-001355","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225001355/ownership.xml","form_type":"4"}},{"id":1024289,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T20:41:43.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 20, 2024, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Readout of AV3-71-SZ-001 schizophrenia study. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares."}],"balance_after":250000,"derivative":{"exercise_price":5.36,"exercise_date":"2025-10-02","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001731122-25-001354","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112225001354/ownership.xml","form_type":"4"}},{"id":1041328,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T19:00:34.000Z","date":"2025-09-11","kind":"exercise","planned":false,"acquired":false,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5.04,"exercise_date":"2018-09-18","expiration_date":"2025-09-18","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0001731122-25-001246","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112225001246/ownership.xml","form_type":"4"}},{"id":1041327,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-12T19:00:34.000Z","date":"2025-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":145048,"price":9.58,"value":1389559.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a \"net exercise\" of outstanding stock options, which options were scheduled to expire on September 18, 2025. The reporting person received 42,452 shares of common stock on net exercise of an option to purchase 187,500 shares of common stock. The Company withheld 145,048 shares of common stock underlying the option as consideration for the exercise price and tax withholdings, using the closing price on September 11, 2025 of $9.58, pursuant to the terms of the Company's 2015 Stock Option Plan."}],"balance_after":1510165,"source":{"system":"sec-edgar","filing":"0001731122-25-001246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112225001246/ownership.xml","form_type":"4"}},{"id":1041326,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-12T19:00:34.000Z","date":"2025-09-11","kind":"exercise","planned":false,"acquired":true,"shares":187500,"price":5.04,"value":945000.0,"ownership":{"direct":true},"balance_after":1655213,"source":{"system":"sec-edgar","filing":"0001731122-25-001246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112225001246/ownership.xml","form_type":"4"}},{"id":1057646,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-22T21:30:21.000Z","date":"2025-08-20","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of preclinical blarcamesine prevention AD data. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares."}],"balance_after":12500,"derivative":{"exercise_price":8.58,"exercise_date":"2025-08-20","expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001731122-25-001168","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225001168/ownership.xml","form_type":"4"}},{"id":1057658,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-22T17:30:05.000Z","date":"2025-08-20","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2025, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of preclinical blarcamesine prevention AD data. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares."}],"balance_after":125000,"derivative":{"exercise_price":8.58,"exercise_date":"2025-08-20","expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001731122-25-001167","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112225001167/ownership.xml","form_type":"4"}},{"id":1117555,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":78717,"kind":"person","name":"Thomas Steffen","position":1,"cik":"0001646396","reported_name":"Thomas Steffen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T21:30:47.000Z","date":"2025-06-05","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested in three equal annual installments beginning on June 15, 2016"}],"balance_after":0,"derivative":{"exercise_price":1.76,"expiration_date":"2025-06-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-25-000837","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000837/ownership.xml","form_type":"4"}},{"id":1117554,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":78717,"kind":"person","name":"Thomas Steffen","position":1,"cik":"0001646396","reported_name":"Thomas Steffen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-06-09T21:30:47.000Z","date":"2025-06-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":11349,"price":7.75,"value":87954.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a \"net exercise\" of outstanding stock options, which options were scheduled to expire on June 15, 2025. The reporting person received 38,651 shares of common stock on net exercise of an option to purchase 50,000 shares of common stock. The Company withheld 11,349 shares of common stock underlying the option as consideration for the exercise price, using the average of the high and low sales price on June 5, 2025 of $7.75, pursuant to the terms of the Company's 2007 Stock Option Plan."}],"balance_after":43651,"source":{"system":"sec-edgar","filing":"0001731122-25-000837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000837/ownership.xml","form_type":"4"}},{"id":1117553,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":78717,"kind":"person","name":"Thomas Steffen","position":1,"cik":"0001646396","reported_name":"Thomas Steffen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-06-09T21:30:47.000Z","date":"2025-06-05","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":1.76,"value":88000.0,"ownership":{"direct":true},"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001731122-25-000837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000837/ownership.xml","form_type":"4"}},{"id":1163282,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-01T00:00:38.000Z","date":"2025-04-28","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2023, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was completion of enrollment of ANAVEX3-71 Phase 2 clinical trial in Schizophrenia. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares."}],"balance_after":12500,"derivative":{"exercise_price":8.57,"exercise_date":"2025-04-28","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001731122-25-000655","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000655/ownership.xml","form_type":"4"}},{"id":1163290,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-30T20:00:22.000Z","date":"2025-04-28","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was completion of enrollment of ANAVEX3-71 Phase 2 clinical trial in Schizophrenia. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares."}],"balance_after":125000,"derivative":{"exercise_price":8.57,"exercise_date":"2025-04-28","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001731122-25-000654","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112225000654/ownership.xml","form_type":"4"}},{"id":1182854,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81213,"kind":"person","name":"Donhauser Peter D.O.","position":1,"cik":"0001698234","reported_name":"Donhauser Peter D.O.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T01:47:21.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning on March 31, 2026"}],"balance_after":50000,"derivative":{"exercise_price":8.58,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-25-000518","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000518/ownership.xml","form_type":"4"}},{"id":1183770,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":45702,"kind":"person","name":"Ma Jiong","position":1,"cik":"0001854872","reported_name":"Ma Jiong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T01:46:45.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning on March 31, 2026"}],"balance_after":50000,"derivative":{"exercise_price":8.58,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-25-000517","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854872/000173112225000517/ownership.xml","form_type":"4"}},{"id":1182853,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81212,"kind":"person","name":"Skarpelos Athanasios","position":1,"cik":"0001360570","reported_name":"Skarpelos Athanasios","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T01:46:27.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning on March 31, 2026"}],"balance_after":50000,"derivative":{"exercise_price":8.58,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-25-000516","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000516/ownership.xml","form_type":"4"}},{"id":1182852,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":78717,"kind":"person","name":"Thomas Steffen","position":1,"cik":"0001646396","reported_name":"Thomas Steffen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T01:45:40.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning on March 31, 2026"}],"balance_after":50000,"derivative":{"exercise_price":8.58,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-25-000515","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000515/ownership.xml","form_type":"4"}},{"id":1182851,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81211,"kind":"person","name":"Velden Claus Vander","position":1,"cik":"0001733908","reported_name":"Velden Claus Vander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T01:45:23.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning on March 31, 2026"}],"balance_after":50000,"derivative":{"exercise_price":8.58,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-25-000514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000514/ownership.xml","form_type":"4"}},{"id":1190718,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-26T21:30:31.000Z","date":"2025-03-24","kind":"exercise","planned":false,"acquired":false,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.92,"exercise_date":"2015-04-02","expiration_date":"2025-04-02","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001731122-25-000452","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112225000452/ownership.xml","form_type":"4"}},{"id":1190717,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-26T21:30:31.000Z","date":"2025-03-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":282497,"price":9.63,"value":2720446.11,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a \"net exercise\" of outstanding stock options, which options were scheduled to expire on April 2, 2025. The reporting person received 217,503 shares of common stock on net exercise of an option to purchase 500,000 shares of common stock. The Company withheld 282,497 shares of common stock underlying the option as consideration for the exercise price and tax withholdings, using the average of the high and low sales price on March 24, 2025 of $9.63, pursuant to the terms of the Company's 2007 Stock Option Plan."}],"balance_after":1467713,"source":{"system":"sec-edgar","filing":"0001731122-25-000452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112225000452/ownership.xml","form_type":"4"}},{"id":1190716,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-26T21:30:31.000Z","date":"2025-03-24","kind":"exercise","planned":false,"acquired":true,"shares":500000,"price":0.92,"value":460000.0,"ownership":{"direct":true},"balance_after":1750210,"source":{"system":"sec-edgar","filing":"0001731122-25-000452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112225000452/ownership.xml","form_type":"4"}},{"id":1299829,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-18T02:12:55.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2023, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of AD-004 Alzheimer's disease study. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares."}],"balance_after":12500,"derivative":{"exercise_price":8.57,"exercise_date":"2025-01-15","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001731122-25-000095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000095/ownership.xml","form_type":"4"}},{"id":1299870,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-17T21:14:04.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of AD-004 Alzheimer's disease study. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares."}],"balance_after":125000,"derivative":{"exercise_price":8.57,"exercise_date":"2025-01-15","expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001731122-25-000096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112225000096/ownership.xml","form_type":"4"}},{"id":1299869,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-17T21:14:04.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":166666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 14, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in three equal tranches based on performance milestones, one of which was completion of Phase 2b/3 study for Alzheimer's disease. The performance criteria for this milestone was met with the final publication of all clinical trial data, resulting in vesting of the option as to 166,000 shares."}],"balance_after":166000,"derivative":{"exercise_price":7.54,"exercise_date":"2025-01-15","expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":166000},"source":{"system":"sec-edgar","filing":"0001731122-25-000096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112225000096/ownership.xml","form_type":"4"}},{"id":1322691,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-24T00:00:31.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 20, 2024, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was regulatory submission of AD-004 for Alzheimer's disease (US or EU). The performance criteria for this milestone was met with the acceptance of the MAA filing by the EMA, resulting in vesting of the option as to 12,500 shares."}],"balance_after":12500,"derivative":{"exercise_price":5.36,"exercise_date":"2024-12-19","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001731122-24-002045","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224002045/ownership.xml","form_type":"4"}},{"id":1322711,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-23T19:00:17.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 20, 2024, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was regulatory submission of AD-004 for Alzheimer's disease (US or EU). The performance criteria for this milestone was met with the acceptance of the MAA filing by the EMA, resulting in vesting of the option as to 125,000 shares."}],"balance_after":125000,"derivative":{"exercise_price":5.36,"exercise_date":"2024-12-19","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001731122-24-002044","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112224002044/ownership.xml","form_type":"4"}},{"id":1340230,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-07T02:00:08.000Z","date":"2024-11-19","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 27, 2022, the reporting person was granted an option to purchase 40,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included completion of the Clinical Study Report for Phase 2a/b AD-004 Alzheimer's disease study. The performance criteria for this milestone was met in connection with the Marketing Authorization Application filing, resulting in vesting of the option as to 10,000 shares."}],"balance_after":20000,"derivative":{"exercise_price":10.09,"exercise_date":"2024-11-19","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001731122-24-001952","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224001952/ownership.xml","form_type":"4"}},{"id":1340248,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-06T21:00:23.000Z","date":"2024-11-19","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 27, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included completion of the Clinical Study Report for Phase 2a/b AD-004 Alzheimer's disease study. The performance criteria for this milestone was met in connection with the Marketing Authorization Application filing, resulting in vesting of the option as to 125,000 shares."}],"balance_after":250000,"derivative":{"exercise_price":10.09,"exercise_date":"2024-11-19","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001731122-24-001953","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112224001953/ownership.xml","form_type":"4"}},{"id":1477009,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81213,"kind":"person","name":"Donhauser Peter D.O.","position":1,"cik":"0001698234","reported_name":"Donhauser Peter D.O.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-17T11:30:10.000Z","date":"2024-06-14","kind":"purchase","planned":false,"acquired":true,"shares":2835,"price":3.64,"value":10319.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Purchase price denominated in Euros has been translated to US dollars using an exchange rate of 0.936"}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001731122-24-000957","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224000957/ownership.xml","form_type":"4"}},{"id":1510841,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":78717,"kind":"person","name":"Thomas Steffen","position":1,"cik":"0001646396","reported_name":"Thomas Steffen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-17T10:01:00.000Z","date":"2024-05-15","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":4.52,"value":22600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Purchase price denominated in Euros has been translated to US dollars using an exchange rate of 0.92"}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001731122-24-000828","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224000828/ownership.xml","form_type":"4"}},{"id":1556038,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-01T18:00:20.000Z","date":"2024-03-28","kind":"exercise","planned":false,"acquired":false,"shares":73380,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.32,"exercise_date":"2014-05-08","expiration_date":"2024-05-08","underlying":"Common Stock","underlying_shares":73380},"source":{"system":"sec-edgar","filing":"0001731122-24-000552","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112224000552/ownership.xml","form_type":"4"}},{"id":1556037,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-04-01T18:00:20.000Z","date":"2024-03-28","kind":"sale","planned":false,"acquired":false,"shares":73380,"price":5.11,"value":374971.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":1250210,"source":{"system":"sec-edgar","filing":"0001731122-24-000552","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112224000552/ownership.xml","form_type":"4"}},{"id":1556036,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-04-01T18:00:20.000Z","date":"2024-03-28","kind":"exercise","planned":false,"acquired":true,"shares":73380,"price":1.32,"value":96861.6,"ownership":{"direct":true},"balance_after":1323590,"source":{"system":"sec-edgar","filing":"0001731122-24-000552","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112224000552/ownership.xml","form_type":"4"}},{"id":1622132,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81213,"kind":"person","name":"Donhauser Peter D.O.","position":1,"cik":"0001698234","reported_name":"Donhauser Peter D.O.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-23T11:05:18.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in equal installments over three years from the grant date."}],"balance_after":50000,"derivative":{"exercise_price":5.36,"exercise_date":"2025-02-20","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-24-000297","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224000297/ownership.xml","form_type":"4"}},{"id":1622131,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":78717,"kind":"person","name":"Thomas Steffen","position":1,"cik":"0001646396","reported_name":"Thomas Steffen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-23T11:04:32.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in equal installments over three years from the grant date."}],"balance_after":50000,"derivative":{"exercise_price":5.36,"exercise_date":"2025-02-20","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-24-000295","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224000295/ownership.xml","form_type":"4"}},{"id":1622130,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81211,"kind":"person","name":"Velden Claus Vander","position":1,"cik":"0001733908","reported_name":"Velden Claus Vander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-23T11:04:31.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in equal installments over three years from the grant date."}],"balance_after":50000,"derivative":{"exercise_price":5.36,"exercise_date":"2025-02-20","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-24-000296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224000296/ownership.xml","form_type":"4"}},{"id":1622820,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":45702,"kind":"person","name":"Ma Jiong","position":1,"cik":"0001854872","reported_name":"Ma Jiong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-23T11:03:48.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in equal installments over three years from the grant date."}],"balance_after":50000,"derivative":{"exercise_price":5.36,"exercise_date":"2025-02-20","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-24-000294","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854872/000173112224000294/ownership.xml","form_type":"4"}},{"id":1622129,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81212,"kind":"person","name":"Skarpelos Athanasios","position":1,"cik":"0001360570","reported_name":"Skarpelos Athanasios","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-23T11:03:06.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in equal installments over three years from the grant date."}],"balance_after":50000,"derivative":{"exercise_price":5.36,"exercise_date":"2025-02-20","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-24-000293","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224000293/ownership.xml","form_type":"4"}},{"id":1679851,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-13T01:00:34.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On June 27, 2022, the reporting person was granted an option to purchase 40,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 10,000 shares."}],"balance_after":10000,"derivative":{"exercise_price":10.09,"exercise_date":"2024-01-02","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001731122-24-000069","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224000069/ownership.xml","form_type":"4"}},{"id":1679859,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-12T20:00:46.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":false,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On June 27, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares."}],"balance_after":125000,"derivative":{"exercise_price":10.09,"exercise_date":"2024-01-02","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001731122-24-000070","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112224000070/ownership.xml","form_type":"4"}},{"id":1840923,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-30T20:00:21.000Z","date":"2023-06-29","kind":"exercise","planned":false,"acquired":false,"shares":232000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.6,"exercise_date":"2013-07-05","expiration_date":"2023-07-05","underlying":"Common Stock","underlying_shares":232000},"source":{"system":"sec-edgar","filing":"0001731122-23-001246","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112223001246/ownership.xml","form_type":"4"}},{"id":1840922,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-30T20:00:21.000Z","date":"2023-06-28","kind":"exercise","planned":false,"acquired":false,"shares":268000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":232000,"derivative":{"exercise_price":1.6,"exercise_date":"2013-07-05","expiration_date":"2023-07-05","underlying":"Common Stock","underlying_shares":268000},"source":{"system":"sec-edgar","filing":"0001731122-23-001246","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112223001246/ownership.xml","form_type":"4"}},{"id":1840921,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-30T20:00:21.000Z","date":"2023-06-29","kind":"exercise","planned":false,"acquired":true,"shares":232000,"price":1.6,"value":371200.0,"ownership":{"direct":true},"balance_after":1250210,"source":{"system":"sec-edgar","filing":"0001731122-23-001246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112223001246/ownership.xml","form_type":"4"}},{"id":1840920,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-30T20:00:21.000Z","date":"2023-06-28","kind":"sale","planned":false,"acquired":false,"shares":268000,"price":7.9825,"value":2139310.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.95 to $8.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":1018210,"source":{"system":"sec-edgar","filing":"0001731122-23-001246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112223001246/ownership.xml","form_type":"4"}},{"id":1840919,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-30T20:00:21.000Z","date":"2023-06-28","kind":"exercise","planned":false,"acquired":true,"shares":268000,"price":1.6,"value":428800.0,"ownership":{"direct":true},"balance_after":1286210,"source":{"system":"sec-edgar","filing":"0001731122-23-001246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112223001246/ownership.xml","form_type":"4"}},{"id":1928808,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":45702,"kind":"person","name":"Ma Jiong","position":1,"cik":"0001854872","reported_name":"Ma Jiong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-04T21:31:34.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in equal instalments over three years from the grant date"}],"balance_after":50000,"derivative":{"exercise_price":8.57,"exercise_date":"2024-03-31","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-23-000585","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854872/000173112223000585/ownership.xml","form_type":"4"}},{"id":1927248,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":78717,"kind":"person","name":"Thomas Steffen","position":1,"cik":"0001646396","reported_name":"Thomas Steffen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-04T21:31:15.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in equal instalments over three years from the grant date"}],"balance_after":50000,"derivative":{"exercise_price":8.57,"exercise_date":"2024-03-31","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-23-000584","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112223000584/ownership.xml","form_type":"4"}},{"id":1927247,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81211,"kind":"person","name":"Velden Claus Vander","position":1,"cik":"0001733908","reported_name":"Velden Claus Vander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-04T21:31:06.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in equal instalments over three years from the grant date"}],"balance_after":50000,"derivative":{"exercise_price":8.57,"exercise_date":"2024-03-31","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-23-000583","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112223000583/ownership.xml","form_type":"4"}},{"id":1927246,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81213,"kind":"person","name":"Donhauser Peter D.O.","position":1,"cik":"0001698234","reported_name":"Donhauser Peter D.O.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-04T21:30:44.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in equal instalments over three years from the grant date"}],"balance_after":50000,"derivative":{"exercise_price":8.57,"exercise_date":"2024-03-31","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-23-000582","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112223000582/ownership.xml","form_type":"4"}},{"id":1927245,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81212,"kind":"person","name":"Skarpelos Athanasios","position":1,"cik":"0001360570","reported_name":"Skarpelos Athanasios","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-04T21:30:31.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in equal instalments over three years from the grant date"}],"balance_after":50000,"derivative":{"exercise_price":8.57,"exercise_date":"2024-03-31","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-23-000581","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112223000581/ownership.xml","form_type":"4"}},{"id":2219258,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81211,"kind":"person","name":"Velden Claus Vander","position":1,"cik":"0001733908","reported_name":"Velden Claus Vander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T21:23:31.000Z","date":"2022-06-27","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":10.09,"exercise_date":"2023-06-27","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-22-001150","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222001150/ownership.xml","form_type":"4"}},{"id":2219257,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":78717,"kind":"person","name":"Thomas Steffen","position":1,"cik":"0001646396","reported_name":"Thomas Steffen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T21:14:43.000Z","date":"2022-06-27","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":10.09,"exercise_date":"2023-06-27","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-22-001147","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222001147/ownership.xml","form_type":"4"}},{"id":2219255,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81213,"kind":"person","name":"Donhauser Peter D.O.","position":1,"cik":"0001698234","reported_name":"Donhauser Peter D.O.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T21:12:13.000Z","date":"2022-06-27","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":10.09,"exercise_date":"2023-06-27","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-22-001145","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222001145/ownership.xml","form_type":"4"}},{"id":2219256,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81212,"kind":"person","name":"Skarpelos Athanasios","position":1,"cik":"0001360570","reported_name":"Skarpelos Athanasios","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T21:10:20.000Z","date":"2022-06-27","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":10.09,"exercise_date":"2023-06-27","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-22-001143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222001143/ownership.xml","form_type":"4"}},{"id":2219437,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":45702,"kind":"person","name":"Ma Jiong","position":1,"cik":"0001854872","reported_name":"Ma Jiong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T21:08:41.000Z","date":"2022-06-27","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":10.09,"exercise_date":"2023-06-27","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-22-001141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854872/000173112222001141/ownership.xml","form_type":"4"}},{"id":2252957,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81212,"kind":"person","name":"Skarpelos Athanasios","position":1,"cik":"0001360570","reported_name":"Skarpelos Athanasios","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-28T00:30:22.000Z","date":"2022-05-25","kind":"exercise","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options subject to this grant vested quarterly over a three-year period commencing on April 2, 2015."}],"balance_after":0,"derivative":{"exercise_price":0.92,"expiration_date":"2025-04-02","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-22-001013","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222001013/ownership.xml","form_type":"4"}},{"id":2252956,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81212,"kind":"person","name":"Skarpelos Athanasios","position":1,"cik":"0001360570","reported_name":"Skarpelos Athanasios","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-28T00:30:22.000Z","date":"2022-05-25","kind":"sale","acquired":false,"shares":50000,"price":9.06,"value":453000.0,"ownership":{"direct":true},"balance_after":1306458,"source":{"system":"sec-edgar","filing":"0001731122-22-001013","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222001013/ownership.xml","form_type":"4"}},{"id":2252955,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81212,"kind":"person","name":"Skarpelos Athanasios","position":1,"cik":"0001360570","reported_name":"Skarpelos Athanasios","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-28T00:30:22.000Z","date":"2022-05-25","kind":"exercise","acquired":true,"shares":50000,"price":0.92,"value":46000.0,"ownership":{"direct":true},"balance_after":1356458,"source":{"system":"sec-edgar","filing":"0001731122-22-001013","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222001013/ownership.xml","form_type":"4"}},{"id":2615307,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":45702,"kind":"person","name":"Ma Jiong","position":1,"cik":"0001854872","reported_name":"Ma Jiong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-04T21:40:59.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":18.11,"exercise_date":"2022-08-02","expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-21-001306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854872/000173112221001306/ownership.xml","form_type":"4"}},{"id":2614488,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81211,"kind":"person","name":"Velden Claus Vander","position":1,"cik":"0001733908","reported_name":"Velden Claus Vander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-04T21:38:51.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":18.11,"exercise_date":"2022-08-02","expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-21-001304","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001304/ownership.xml","form_type":"4"}},{"id":2614487,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-04T21:36:14.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest upon achieving a key enrollment milestone in a late stage clinical study."}],"balance_after":40000,"derivative":{"exercise_price":18.11,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001731122-21-001302","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001302/ownership.xml","form_type":"4"}},{"id":2614486,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81213,"kind":"person","name":"Donhauser Peter D.O.","position":1,"cik":"0001698234","reported_name":"Donhauser Peter D.O.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-04T21:30:37.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":18.11,"exercise_date":"2022-08-02","expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-21-001300","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001300/ownership.xml","form_type":"4"}},{"id":2614485,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":78717,"kind":"person","name":"Thomas Steffen","position":1,"cik":"0001646396","reported_name":"Thomas Steffen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-04T21:26:04.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":18.11,"exercise_date":"2022-08-02","expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-21-001296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001296/ownership.xml","form_type":"4"}},{"id":2614484,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81212,"kind":"person","name":"Skarpelos Athanasios","position":1,"cik":"0001360570","reported_name":"Skarpelos Athanasios","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-04T21:22:28.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":18.11,"exercise_date":"2022-08-02","expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-21-001294","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001294/ownership.xml","form_type":"4"}},{"id":2614533,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-04T17:19:40.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest upon achieving a key enrollment milestone in a late stage clinical study."}],"balance_after":500000,"derivative":{"exercise_price":18.11,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001731122-21-001292","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112221001292/ownership.xml","form_type":"4"}},{"id":2647293,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options subject to this grant vested quarterly over a three-year period commencing on June 30, 2017."}],"balance_after":0,"derivative":{"exercise_price":5.92,"expiration_date":"2027-05-12","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647292,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":106696,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.28,"exercise_date":"2016-09-22","expiration_date":"2026-09-22","underlying":"Common Stock","underlying_shares":106696},"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647291,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options subject to this grant vested quarterly over a three-year period commencing on December 31, 2015."}],"balance_after":0,"derivative":{"exercise_price":5.68,"expiration_date":"2025-10-02","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647290,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":166696,"price":26.53,"value":4422444.88,"ownership":{"direct":true},"balance_after":22963,"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647289,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":35000,"price":5.92,"value":207200.0,"ownership":{"direct":true},"balance_after":189659,"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647288,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":106696,"price":3.28,"value":349962.88,"ownership":{"direct":true},"balance_after":154659,"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647287,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":25000,"price":5.68,"value":142000.0,"ownership":{"direct":true},"balance_after":47963,"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647335,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-01T21:48:40.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":51620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options subject to this grant vested over 4 years on May 8, 2015, May 8, 2016, May 8, 2017, May 8, 2018."}],"balance_after":73380,"derivative":{"exercise_price":1.32,"expiration_date":"2024-05-08","underlying":"Common Stock","underlying_shares":51620},"source":{"system":"sec-edgar","filing":"0001731122-21-001127","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112221001127/ownership.xml","form_type":"4"}},{"id":2647334,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-07-01T21:48:40.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":51620,"price":26,"value":1342120.0,"ownership":{"direct":true},"balance_after":1018210,"source":{"system":"sec-edgar","filing":"0001731122-21-001127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112221001127/ownership.xml","form_type":"4"}},{"id":2647333,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69645,"kind":"person","name":"MISSLING CHRISTOPHER U","position":1,"cik":"0001196573","reported_name":"MISSLING CHRISTOPHER U","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-07-01T21:48:40.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":51620,"price":1.32,"value":68138.4,"ownership":{"direct":true},"balance_after":1069830,"source":{"system":"sec-edgar","filing":"0001731122-21-001127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196573/000173112221001127/ownership.xml","form_type":"4"}},{"id":2696658,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.96,"exercise_date":"2021-01-06","expiration_date":"2030-01-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696657,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":6.11,"exercise_date":"2016-06-30","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696656,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5.66,"exercise_date":"2016-04-27","expiration_date":"2026-04-27","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696655,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":4.9,"exercise_date":"2016-03-31","expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696654,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5.57,"exercise_date":"2015-12-31","expiration_date":"2025-12-31","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696653,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5.64,"exercise_date":"2015-12-31","expiration_date":"2025-09-30","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696652,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.92,"exercise_date":"2015-04-02","expiration_date":"2025-04-02","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696651,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.2,"exercise_date":"2015-05-07","expiration_date":"2024-05-07","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696650,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"sale","acquired":false,"shares":145000,"price":11.6985,"value":1696282.5,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696649,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":true,"shares":50000,"price":2.96,"value":148000.0,"ownership":{"direct":true},"balance_after":145000,"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696648,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":true,"shares":1500,"price":6.11,"value":9165.0,"ownership":{"direct":true},"balance_after":95000,"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696647,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":true,"shares":1500,"price":5.66,"value":8490.0,"ownership":{"direct":true},"balance_after":93500,"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696646,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":true,"shares":1500,"price":4.9,"value":7350.0,"ownership":{"direct":true},"balance_after":92000,"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696645,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":true,"shares":1500,"price":5.57,"value":8355.0,"ownership":{"direct":true},"balance_after":90500,"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696644,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":true,"shares":1500,"price":5.64,"value":8460.0,"ownership":{"direct":true},"balance_after":89000,"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696643,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":true,"shares":50000,"price":0.92,"value":46000.0,"ownership":{"direct":true},"balance_after":87500,"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2696642,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-26T01:30:48.000Z","date":"2021-05-21","kind":"exercise","acquired":true,"shares":37500,"price":1.2,"value":45000.0,"ownership":{"direct":true},"balance_after":37500,"source":{"system":"sec-edgar","filing":"0001731122-21-000941","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000941/ownership.xml","form_type":"4"}},{"id":2705078,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":81213,"kind":"person","name":"Donhauser Peter D.O.","position":1,"cik":"0001698234","reported_name":"Donhauser Peter D.O.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-19T12:47:25.000Z","date":"2021-05-17","kind":"purchase","acquired":true,"shares":1000,"price":10.93,"value":10930.0,"ownership":{"direct":true},"balance_after":2165,"source":{"system":"sec-edgar","filing":"0001731122-21-000916","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000916/ownership.xml","form_type":"4"}},{"id":2829235,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-27T02:31:59.000Z","date":"2021-02-24","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.28,"exercise_date":"2016-09-22","expiration_date":"2026-09-22","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001731122-21-000308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000308/ownership.xml","form_type":"4"}},{"id":2829234,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":139057,"kind":"person","name":"FAVUS ELLIOT","position":1,"cik":"0001608022","reported_name":"FAVUS ELLIOT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-27T02:31:59.000Z","date":"2021-02-24","kind":"exercise","acquired":false,"shares":45500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vested upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials."}],"balance_after":0,"derivative":{"exercise_price":2.58,"expiration_date":"2028-10-01","underlying":"Common Stock","underlying_shares":45500},"source":{"system":"sec-edgar","filing":"0001731122-21-000308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000308/ownership.xml","form_type":"4"}}],"next_cursor":"2021-02-27T02:31:59.000000Z,2829234"}